Boceprevir Capsules (Victrelisâ„¢)

Elliott, William T.; Chan, James
June 2011
Internal Medicine Alert;6/15/2011, Vol. 33 Issue 11, p84
Product Review
The article evaluates the boceprevir capsule Victrelis, a protease inhibitor for the treatment of chronic hepatitis C (HCV) infections, from Merck & Co. Inc.


Related Articles

  • VICTRELIS.  // MPR - Residents' Edition;Fall/Winter2011, Vol. 20 Issue 2, pA:7 

    The article offers brief clinical and pharmacological information on Victrelis, a hepatitis c virus protease inhibitor with boceprevir for treatment of chronic hepatitis C genotype 1 infection from Merck & Co. Inc.

  • Boceprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p203 

    Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C virus (HCV) inhibitors. It is being developed by Merck & Co. as part of a combination therapy regimen for the treatment of HCV infections. In two phase III trials,...

  • Two new drugs for hepatitis C. Elliott, William T. // Neurology Alert;Jul2011 Clinical Briefs in Primary, p1 

    The article reports that two drugs for the treatment of hepatitis C were approved by the U.S. Food and Drug Administration (FDA). The drugs have similar indicators and are protease inhibitors. The first drug to be approved was boceprevir (Victrelis) manufactured by Merck and indicated for adults...

  • Telaprevir Looks Ever-Better, But Don't Discount Boceprevir. Morrison, Trista // BioWorld Insight;8/16/2010, Vol. 18 Issue 33, p3 

    The article reports on the competition in the development of effective pharmacology for hepatitis C virus (HCV). Accordingly, Vertex Pharmaceuticals Inc. has reported a 75 percent HCV cure rate from the protease inhibitor telaprevir, while the boceprevir from Merck & Co. Inc. has reported a 66...

  • VICTRELIS(tm) (boceprevir) Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection.  // Biomedical Market Newsletter;5/28/2011, p333 

    The article reports on the approval of Merck & Co. Inc.'s investigational medicine Victrelis boceprevir to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection by the by the U.S. Food and Drug Administration (FDA) Advisory Committee. Merck's Victrelis is one of the new drugs...

  • Telaprevir's Response-Guided rial Helps HCV Get Personal. Morrison, Trista // BioWorld Insight;5/31/2010, Vol. 18 Issue 22, p3 

    The article focuses on the concept of Vertex Pharmaceuticals Inc. and Merck & Co. Inc. on using early viral load measurements in the Phase III trials of their Hepatitis C virus (HCV) protease inhibitors, telaprevir and boceprevir. It says that protease inhibitors allowed patients to achieve an...

  • Therapeutics: New drugs hit the target. Schlütter, Jana // Nature;6/9/2011 Supplement, Vol. 474 Issue 7350, pS5 

    The article offers information on the drugs for treating hepatitis C virus (HCV) such as telaprevir, a protease inhibitors from Vertex Pharmaceuticals Inc. and boceprevir from Merck and Co. Inc. It says that the new drugs targets directly the HCV especially its NS3/4A serine protease. However,...

  • BioWorld's Top 10 Countdown Of 2012's Most Impactful Stories.  // BioWorld International;1/2/2013, Vol. 18 Issue 1, p1 

    The article offers world updates on the developments in the pharmaceutical biotechnology industry in 2012. Protease inhibitors Incivek from Vertex Pharmaceuticals Inc. and Victrelis from Merck & Co. Inc. have been approved for the treatment of hepatitis C virus (HCV) infection. Humira...

  • HCV THERAPIES READY TO TIP.  // Applied Clinical Trials;Sep2010, Vol. 19 Issue 9, p16 

    The article focuses on medical research to improve the treatments for the hepatitis C virus (HCV) in the U.S. Merck & Co. Inc. and Vertex Pharmaceuticals Inc. have plans to conduct investigational treatments for HCV therapies. It discusses their use of boceprevir and telapriver, which are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics